DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

NPPA sets retail prices for 41 drug combinations, including 18 variants of off-patent diabetes drug empagliflozin, following steep price drops post-patent expiry ...

New targeted therapies allow for the treatment of a disease that is already the fifth leading cause of fatal tumors globally ...

The global veterinary dermatology market, valued at US$18.59 billion in 2024, is forecasted to grow at a robust CAGR of 8.5%, ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 26, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

New outcomes from Boehringer Ingelheim Canada's Access for Health Education and Disease Management (AHEAD) program underscores the essential role that allied health professionals and disease ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on 24-25 November for in‑depth case studies, practical workshops and ...

Global pharmaceutical giant Boehringer Ingelheim has signed a new five-year ... The firm develops and markets products for both human and animal health. OMD’s remit includes human and animal ...

Boehringer Ingelheim is a biopharmaceutical company ... information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press ...

ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows.